MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/102.5/0.1/21.03.25 | Market Closed - Börse Stuttgart 03:12:29 2024-07-04 pm EDT | ||
| 0.072 EUR | -4.00% |
|
| Current month | -20.00% | ||
| 1 month | -33.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 0.072 | -4.00% |
| 24-07-03 | 0.075 | -5.06% |
| 24-07-02 | 0.079 | -12.22% |
| 24-07-01 | 0.09 | 0.00% |
| 24-06-28 | 0.09 | -4.26% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 03:12 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG4PAP |
| ISIN | DE000MG4PAP5 |
| Date issued | 2024-05-23 |
| Strike | 102.5 $ |
| Maturity | 2025-03-21 (260 Days) |
| Parity | 10 : 1 |
| Emission price | 0.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.121 € |
|---|---|
| Lowest since issue | 0.07 € |
| Spread | 0.022 € |
| Spread % | 23.40% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
154.5
USD
Average target price
174.6
USD
Spread / Average Target
+12.95%
- Stock Market
- Warrants
- Warrant
